Overview

A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Withdrawn

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate radiographic progression-free survival (PFS) of enzalutamide in chemotherapy-naïve patients with progressive metastatic castration-resistant prostate cancer who have symptomatic disease.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborator:

Medivation, Inc.